Navigation Links
Radiation Before Surgery May Prevent Return of Rectal Cancer
Date:10/25/2010

MONDAY, Oct. 25 (HealthDay News) -- Patients who receive radiation before surgery for rectal cancer are about 50 percent less likely to experience a return of their cancer, a new Dutch study has found.

Local recurrence -- the return of cancer to the original tumor site and surrounding area -- is a major problem in the treatment of rectal cancer patients, explained the researchers from Leiden University Medical Center in the Netherlands.

This recurrence often occurs in lymph nodes in the mesorectum, which is fatty tissue near the rectum. That's why many patients undergo a surgical procedure called total mesorectal excision (TME), which removes the entire mesorectum and lymph nodes, the study authors explained.

The researchers found that radiation treatment before surgery cuts the risk of cancer recurrence after 10 years by about half.

The study included more than 1,800 rectal cancer patients scheduled for TME. They were randomly selected to receive short-term radiation before surgery or surgery alone. Ten years after treatment, the risk of local cancer recurrence was 6 percent in the radiation/surgery group and 11 percent in the surgery-alone group, the investigators reported.

The findings are to be presented Nov. 1 at the American Society for Radiation Oncology (ASTRO) annual meeting, in San Diego.

"We believe that this short course of radiation will open a new window of opportunities in the treatment of rectal cancer," study author and radiation oncologist Dr. Corrie Marijnen said in an ASTRO news release.

She added that the "study suggests that tumors in the middle rectum and stage III rectal cancer patients will most greatly benefit from receiving radiation before surgery."

"Time is an important advance in the surgical management of rectal carcinoma. Unfortunately, the complexity of the anatomy involved is such that even with expert surgery, there are still patients who will experience recurrence of their cancer in the pelvic region, compromising their survival and markedly impairing the quality of their life," explained Dr. Bernadine Donahue, vice chair and clinical director of radiation oncology at Maimonides Cancer Center in New York City.

"The large Dutch experience has helped identify which subsets of patients will benefit from preoperative radiation therapy as a means of decreasing the risk of local recurrence. In the Dutch trial, an intense short course of radiation therapy was delivered prior to surgery. This clearly improved tumor control and that is good news," Donahue noted. "However, most North American facilities deliver [an] equivalent amount of radiation packaged as smaller amounts daily over a longer period of time to decrease the likelihood of long-term toxicity. It remains to be seen what the long-term side effects of the Dutch approach will be."

More information

The U.S. National Cancer Institute has more about treatment of rectal cancer.

-- Robert Preidt

SOURCE: American Society for Radiation Oncology, news release, Oct. 25, 2010; Bernadine Donahue, M.D., vice chair and clinical director, radiation oncology, Maimonides Cancer Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Demand for Radiation Therapy Predicted to Exceed Supply
2. Demand for radiation therapy projected to outpace supply of radiation oncologists
3. Diagnostic techniques help IBD patients avoid ionizing radiation exposure
4. SNM and Image GentlyTM launch initiative to standardize radiation dose in pediatric nuclear medicine
5. Menssana Research Inc. gets $4.2M BARDA contract to develop breath test for radiation
6. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
7. Mayo researchers find biomarkers for personalizing radiation cancer treatment
8. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
9. Novel target for existing drug may improve success of radiation therapy
10. Radiation exposure poses similar risk of first and second cancers in atomic bomb survivors
11. Scientists receive nearly $11 million to develop radiation countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Radiation Before Surgery May Prevent Return of  Rectal Cancer 
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating ... new location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. ... Smart TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing , ... exercise invention which aids in proper muscle development. , "The Gym & Exercise ... Director of World Patent Marketing. "Globalization has threatened the future growth of the ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Reltok Nasal ... and products for the head and neck/ear, nose and throat specialty, has added the ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst ... and coding services, and Deyta Analytics, recently announced the recipients of the fourth ... of quality as measured from the caregiver’s point of view. The official list ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
Breaking Medicine Technology: